According to the Zhixun Finance APP, Haisco Pharmaceuticals (001367.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue of 0.32 billion yuan, a year-on-year increase of 13.02%. It achieved a net income attributable to shareholders of the listed company of 86.95 million yuan, an increase of 20.89% year-on-year, and achieved a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 86.1 million yuan, an increase of 22.87% year-on-year.